Amgen Sp. z o.o. (Poland)

Amgen Sp. z o.o. is the Polish affiliate of Amgen, a leading global biotechnology company focused on discovering, developing, manufacturing and commercialising innovative human therapeutics. In Poland the company is responsible for the registration, market access, medical support and promotion of Amgen prescription medicines, as well as cooperation with healthcare professionals and institutions and participation in global and local clinical research projects. Amgen's business portfolio is concentrated on serious diseases with significant unmet medical needs, and its products include biologic and targeted therapies in such therapeutic areas as oncology and hematology, cardiovascular disease, bone health and osteoporosis, inflammation and autoimmune diseases, nephrology, neurology and selected rare diseases. The company's medicines are used in hospital and specialist outpatient settings and are part of drug programmes and reimbursement schemes in the Polish healthcare system. Amgen Sp. z o.o. operates on the Polish market within the European regional structure of the group, benefiting from global research and development, manufacturing and supply chain capabilities. At group level Amgen's medicines are available in around 100 countries, and the company invests heavily in R&D, using advanced human genetics and molecular engineering technologies to develop new therapies and expand indications for existing products. Key assets associated with the Polish affiliate include a portfolio of innovative biologic medicines and biosimilars, expertise in biologics and biotechnology, relationships with clinical experts and medical societies, and integration into Amgen's global quality and pharmacovigilance systems. Strategically the company positions itself as an innovative biotechnology partner for the healthcare system, focused on introducing therapies with meaningful clinical benefits, supporting evidence-based medicine, and improving patient access through cooperation with regulators, payers and clinical centres, while maintaining high standards of ethics, compliance and patient safety.